Paliperidone
Generic name: Pronounced as (pal ee per' i done)
Medical Content Reviewed By HelloPharmacist Staff
Last Revised - 07/15/2017
On this page
- Why is this medication prescribed?
- How should this medicine be used?
- Other uses for this medicine
- What special precautions should I follow?
- What special dietary instructions should I follow?
- What should I do if I forget a dose?
- What side effects can this medication cause?
- What should I know about STORAGE and DISPOSAL of this medication?
- What should I do in case of OVERDOSE?
- What OTHER INFORMATION should I know?
- Drug interactions
IMPORTANT WARNING
Studies have shown that older adults with dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) who take antipsychotics (medications for mental illness) such as paliperidone have an increased risk of death during treatment. Older adults with dementia may also have a greater chance of having a stroke or ministroke during treatment.
Paliperidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior problems in older adults with dementia. Talk to the doctor who prescribed this medication, if you, a family member, or someone you care for has dementia and is taking paliperidone. For more information, visit the FDA website: http://www.fda.gov/Drugs
Why is this medication prescribed?
Paliperidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Paliperidone is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.
How should this medicine be used?
Paliperidone comes as an extended-release (long-acting) tablet to take by mouth. It is usually taken once a day in the morning with or without food. Take paliperidone at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take paliperidone exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole with plenty of water or other liquid. Do not split, chew, or crush the tablets. Tell your doctor if you cannot swallow tablets. Your doctor will probably prescribe another medication to treat your condition.
Talk to your doctor about how you are feeling during your treatment. If your symptoms are still bothersome, your doctor may gradually increase your dose, not more often than once every 5 days.
Paliperidone controls the symptoms of schizophrenia but does not cure the condition. Continue to take paliperidone even if you feel well. Do not stop taking paliperidone without talking to your doctor.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before taking paliperidone,
-
tell your doctor and pharmacist if you are allergic to paliperidone, risperidone (Risperdal), or any other medications.
-
tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antidepressants; certain antibiotics such as erythromycin (E.E.S., E-Mycin, Erythrocin), gatifloxacin (Tequin) (not available in the United States), moxifloxacin (Avelox), and sparfloxacin (Zagam); certain antipsychotics such as chlopromazine (Sonazine, Thorazine), pimozide (Orap), risperidone (Risperdal) and thioridazine; cisapride (Propulsid); levodopa (in Sinemet, in Stalevo); medications for anxiety, high blood pressure, or seizures; medications for irregular heartbeat such as amiodarone (Cordarone), disopyramide (Norpace), dofetilide (Tikosyn); procainamide (Procanbid, Pronestyl), quinidine (Quinidex), and sotalol (Betapace, Betapace AF); sedatives; sleeping pills; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
-
tell your doctor if you have or have ever had a prolonged QT interval (a rare heart problem that may cause fainting or irregular heartbeat); slow or irregular heartbeat; a heart attack; low levels of potassium or magnesium in your blood; seizures; trouble keeping your balance; a stroke; a head injury; a brain tumor; Parkinson's disease (a disorder of the nervous system that causes difficulties with movement, muscle control, and balance); diabetes; breast cancer; surgery involving the intestines; any condition that causes blockage or narrowing of the esophagus (tube that connects the mouth and stomach), stomach, or intestines such as cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction), and inflammatory bowel disease (IBD; a group of conditions that cause swelling of the lining of the intestines); and kidney, heart, or liver disease. Also tell your doctor if you drink or have ever drunk large amounts of alcohol and if you use or have ever used street drugs or have overused prescription medications. Tell your doctor if you have ever had to stop taking a medication for mental illness because of severe side effects.
-
tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breast-feeding. If you become pregnant while taking paliperidone, call your doctor. Paliperidone may cause problems in newborns following delivery if it is taken during the last months of pregnancy.
-
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking paliperidone.
-
you should know that paliperidone may make you drowsy and may cause difficulty with thinking and movement. Do not drive a car or operate machinery until you know how this medication affects you.
-
you should know that alcohol may add to the drowsiness caused by paliperidone. Do not drink alcoholic beverages while you are taking this medication.
-
you should know that you may experience hyperglycemia (increases in your blood sugar) while you are taking this medication, even if you do not already have diabetes. If you have schizophrenia, you may be more likely to develop diabetes than people who do not have schizophrenia, and taking paliperidone or similar medications may increase this risk. Tell your doctor immediately if you have any of the following symptoms while you are taking paliperidone: extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness. It is very important to call your doctor as soon as you have any of these symptoms, because high blood sugar can cause more serious symptoms, such as dry mouth, nausea and vomiting, shortness of breath, breath that smells fruity, or decreased consciousness, and may become life-threatening if it is not treated at an early stage.
-
you should know that paliperidone may make it harder for your body to cool down when it gets very hot. Tell your doctor if you plan to exercise or be exposed to extreme heat.
-
you should know that paliperidone may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common when you first start taking paliperidone or when your dose is increased. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.
What special dietary instructions should I follow?
Unless your doctor tells you otherwise, continue your normal diet.
What should I do if I forget a dose?
Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
What side effects can this medication cause?
-
Paliperidone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
-
dizziness, feeling unsteady, or having trouble keeping your balance
-
extreme tiredness
-
weakness
-
headache
-
dry mouth
-
increased saliva
-
weight gain
-
stomach pain
-
-
Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:
-
fever
-
muscle pain or stiffness
-
falling
-
confusion
-
fast, pounding, or irregular heartbeat
-
sweating
-
unusual movements of your face or body that you cannot control
-
slow or stiff movements
-
restlessness
-
painful erection of the penis that lasts for hours
-
-
Paliperidone may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
What should I know about STORAGE and DISPOSAL of this medication?
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.
It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org
What should I do in case of OVERDOSE?
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Symptoms of overdose may include:
-
unusual movements of your face or body that you cannot control
-
slow or stiff movements
-
restlessness
-
unsteadiness
-
drowsiness
-
fast heartbeat
What OTHER INFORMATION should I know?
Keep all appointments with your doctor.
Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.
You may notice something that looks like a tablet in your stool. This is just the empty tablet shell and does not mean that you did not get your complete dose of medication.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Drug interactions
Drug | Interaction |
---|---|
Moxifloxacin | Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Paliperidone. |
Repaglinide | Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Paliperidone. |
Insulin Glargine (rDNA origin) Injection | Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Paliperidone. |
Delavirdine | Delavirdine The metabolism of Paliperidone can be decreased when combined with Delavirdine. |
Nevirapine | Nevirapine The metabolism of Paliperidone can be decreased when combined with Nevirapine. |
Atorvastatin | Atorvastatin The metabolism of Paliperidone can be decreased when combined with Atorvastatin. |
Dolasetron | Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Paliperidone. |
Anagrelide | Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Paliperidone. |
Candesartan | Candesartan Paliperidone may decrease the antihypertensive activities of Candesartan. |
Cilostazol | Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Paliperidone. |
Clopidogrel | Clopidogrel The metabolism of Paliperidone can be decreased when combined with Clopidogrel. |
Diphenoxylate | Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paliperidone. |
Erythromycin and Sulfisoxazole | Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Paliperidone. |
Estrogen and Progestin (Oral Contraceptives) | Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Fenofibrate | Fenofibrate Fenofibrate may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Guanfacine | Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Paliperidone. |
Magnesium Hydroxide | Magnesium Hydroxide Paliperidone may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
Methylergonovine | Methylergonovine The risk or severity of hypertension can be increased when Methylergometrine is combined with Paliperidone. |
Miglitol | Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Paliperidone. |
Mycophenolate | Mycophenolate Mycophenolic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Naratriptan | Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone. |
Olsalazine | Olsalazine Olsalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Paregoric | Paregoric The serum concentration of Morphine can be increased when it is combined with Paliperidone. |
Penbutolol | Penbutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Paliperidone. |
Pentazocine | Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone. |
Potassium | Potassium Potassium may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Prednisone | Prednisone Prednisone may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Ranitidine | Ranitidine The metabolism of Paliperidone can be decreased when combined with Ranitidine. |
Reserpine | Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Paliperidone. |
Rizatriptan | Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with Paliperidone. |
Sumatriptan | Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Paliperidone. |
Tacrolimus | Tacrolimus The metabolism of Paliperidone can be decreased when combined with Tacrolimus. |
Tizanidine | Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Paliperidone. |
Triamcinolone | Triamcinolone The metabolism of Paliperidone can be increased when combined with Triamcinolone. |
Zolmitriptan | Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone. |
Ampicillin Injection | Ampicillin Injection Ampicillin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Doxycycline Injection | Doxycycline Injection Doxycycline may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Famotidine Injection | Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Paliperidone. |
Fluconazole Injection | Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Paliperidone. |
Foscarnet Injection | Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Paliperidone. |
Hydromorphone Injection | Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Paliperidone. |
Levofloxacin Injection | Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Paliperidone. |
Meperidine Injection | Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Paliperidone. |
Metoclopramide Injection | Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone. |
Metronidazole Injection | Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Paliperidone. |
Morphine Injection | Morphine Injection The serum concentration of Morphine can be increased when it is combined with Paliperidone. |
Pamidronate Injection | Pamidronate Injection Pamidronic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Vancomycin Injection | Vancomycin Injection Paliperidone may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
Altretamine | Altretamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Amphetamine. |
Cefuroxime | Cefuroxime Cefuroxime may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cyclosporine | Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Paliperidone. |
Ondansetron | Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Paliperidone. |
Granisetron | Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Paliperidone. |
Torsemide | Torsemide Torasemide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Olanzapine | Olanzapine Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Alosetron | Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Paliperidone. |
Dofetilide | Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Paliperidone. |
Entacapone | Entacapone The therapeutic efficacy of Entacapone can be decreased when used in combination with Paliperidone. |
Eprosartan | Eprosartan Paliperidone may decrease the antihypertensive activities of Eprosartan. |
Hydroxychloroquine | Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Paliperidone. |
Meloxicam | Meloxicam Meloxicam may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Oxcarbazepine | Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Paliperidone. |
Pantoprazole | Pantoprazole Pantoprazole may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Telmisartan | Telmisartan Paliperidone may decrease the antihypertensive activities of Telmisartan. |
Temozolomide | Temozolomide Temozolomide may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Zaleplon | Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone. |
Anakinra | Anakinra The metabolism of Paliperidone can be increased when combined with Anakinra. |
Desloratadine | Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Paliperidone. |
Linezolid | Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Paliperidone. |
Trimipramine | Trimipramine Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Etanercept Injection | Etanercept Injection The metabolism of Paliperidone can be increased when combined with Etanercept. |
Glycopyrrolate | Glycopyrrolate Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium. |
Modafinil | Modafinil The metabolism of Paliperidone can be increased when combined with Modafinil. |
Perindopril | Perindopril Perindopril may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Tenofovir | Tenofovir Tenofovir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Choline Magnesium Trisalicylate | Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Sirolimus | Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Paliperidone. |
Dutasteride | Dutasteride The metabolism of Paliperidone can be decreased when combined with Dutasteride. |
Epinephrine Injection | Epinephrine Injection The therapeutic efficacy of Epinephrine can be decreased when used in combination with Paliperidone. |
Eplerenone | Eplerenone Eplerenone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Escitalopram | Escitalopram The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Paliperidone. |
Olmesartan | Olmesartan Paliperidone may decrease the antihypertensive activities of Olmesartan. |
Zonisamide | Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Paliperidone. |
Adalimumab Injection | Adalimumab Injection The metabolism of Paliperidone can be increased when combined with Adalimumab. |
Aripiprazole | Aripiprazole Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Atomoxetine | Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Paliperidone. |
Dexmethylphenidate | Dexmethylphenidate The risk or severity of adverse effects can be increased when Paliperidone is combined with Dexmethylphenidate. |
Atazanavir | Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Paliperidone. |
Almotriptan | Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone. |
Eletriptan | Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone. |
Mefloquine | Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Paliperidone. |
Rosuvastatin | Rosuvastatin The metabolism of Paliperidone can be decreased when combined with Rosuvastatin. |
Vardenafil | Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Paliperidone. |
Alfuzosin | Alfuzosin Alfuzosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Aprepitant | Aprepitant The metabolism of Paliperidone can be decreased when combined with Aprepitant. |
Emtricitabine | Emtricitabine Emtricitabine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Memantine | Memantine The therapeutic efficacy of Memantine can be decreased when used in combination with Paliperidone. |
Tegaserod | Tegaserod The metabolism of Tegaserod can be decreased when combined with Paliperidone. |
Tadalafil | Tadalafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Tadalafil is combined with Paliperidone. |
Frovatriptan | Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Paliperidone. |
Gemifloxacin | Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Paliperidone. |
Progesterone | Progesterone The metabolism of Paliperidone can be decreased when combined with Progesterone. |
Apomorphine Injection | Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Paliperidone. |
Infliximab Injection | Infliximab Injection The metabolism of Paliperidone can be increased when combined with Infliximab. |
Protriptyline | Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Paliperidone. |
Rifaximin | Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Paliperidone. |
Duloxetine | Duloxetine The metabolism of Paliperidone can be decreased when combined with Duloxetine. |
Norethindrone | Norethindrone The metabolism of Paliperidone can be decreased when combined with Norethisterone. |
Tinidazole | Tinidazole Tinidazole may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Trospium | Trospium Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Trospium. |
Bosentan | Bosentan Paliperidone may decrease the antihypertensive activities of Bosentan. |
Cefditoren | Cefditoren Cefdinir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cinacalcet | Cinacalcet The metabolism of Paliperidone can be decreased when combined with Cinacalcet. |
Cyanocobalamin Injection | Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Erlotinib | Erlotinib The metabolism of Paliperidone can be decreased when combined with Erlotinib. |
Eszopiclone | Eszopiclone The risk or severity of CNS depression can be increased when Paliperidone is combined with Eszopiclone. |
Ganciclovir | Ganciclovir Ganciclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Insulin Aspart (rDNA Origin) Injection | Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Paliperidone. |
Ribavirin | Ribavirin Ribavirin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Solifenacin | Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Paliperidone. |
Valganciclovir | Valganciclovir Paliperidone may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
Voriconazole | Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Paliperidone. |
Adefovir | Adefovir Adefovir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Dextroamphetamine | Dextroamphetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Amphetamine. |
Peginterferon Alfa-2b (PEG-Intron) | Peginterferon Alfa-2b (PEG-Intron) The metabolism of Paliperidone can be decreased when combined with Peginterferon alfa-2b. |
Pramlintide Injection | Pramlintide Injection The therapeutic efficacy of Pramlintide can be decreased when used in combination with Paliperidone. |
Sodium Oxybate | Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. |
Exenatide Injection | Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Paliperidone. |
Ibandronate | Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paliperidone. |
Isocarboxazid | Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paliperidone. |
Ramelteon | Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Paliperidone. |
Darifenacin | Darifenacin The metabolism of Darifenacin can be decreased when combined with Paliperidone. |
Fentanyl | Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Paliperidone. |
Pregabalin | Pregabalin The therapeutic efficacy of Paliperidone can be increased when used in combination with Pregabalin. |
Phenylephrine | Phenylephrine The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Paliperidone. |
Tipranavir | Tipranavir The serum concentration of Tipranavir can be decreased when it is combined with Paliperidone. |
Felbamate | Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Paliperidone. |
Insulin Detemir (rDNA Origin) Injection | Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Paliperidone. |
Ranolazine | Ranolazine The serum concentration of Paliperidone can be increased when it is combined with Ranolazine. |
Abatacept Injection | Abatacept Injection The metabolism of Paliperidone can be increased when combined with Abatacept. |
Rasagiline | Rasagiline The risk or severity of adverse effects can be increased when Paliperidone is combined with Rasagiline. |
Imatinib | Imatinib The risk or severity of QTc prolongation can be increased when Imatinib is combined with Paliperidone. |
Sitagliptin | Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Paliperidone. |
Varenicline | Varenicline Paliperidone may decrease the excretion rate of Varenicline which could result in a higher serum level. |
Gefitinib | Gefitinib The metabolism of Paliperidone can be decreased when combined with Gefitinib. |
Albuterol | Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Paliperidone. |
Bortezomib | Bortezomib The serum concentration of Paliperidone can be increased when it is combined with Bortezomib. |
Clofarabine Injection | Clofarabine Injection Clofarabine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Insulin Glulisine (rDNA origin) Injection | Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Paliperidone. |
Lubiprostone | Lubiprostone Lubiprostone may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Oxaliplatin Injection | Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Paliperidone. |
Posaconazole | Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Paliperidone. |
Primaquine | Primaquine The metabolism of Paliperidone can be decreased when combined with Primaquine. |
Aliskiren | Aliskiren Paliperidone may decrease the antihypertensive activities of Aliskiren. |
Bismuth Subsalicylate | Bismuth Subsalicylate Paliperidone may increase the neurotoxic activities of Bismuth subsalicylate. |
Pemetrexed Injection | Pemetrexed Injection Paliperidone may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
Dimenhydrinate | Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Paliperidone. |
Lisdexamfetamine | Lisdexamfetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Lisdexamfetamine. |
Nabilone | Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. |
Vorinostat | Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Paliperidone. |
Sorafenib | Sorafenib The metabolism of Paliperidone can be decreased when combined with Sorafenib. |
Sunitinib | Sunitinib The metabolism of Paliperidone can be decreased when combined with Sunitinib. |
Dronabinol | Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. |
Lapatinib | Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Paliperidone. |
Levocetirizine | Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Paliperidone. |
Pegaptanib Injection | Pegaptanib Injection Paliperidone may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
Dasatinib | Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Paliperidone. |
Mexiletine | Mexiletine The metabolism of Paliperidone can be decreased when combined with Mexiletine. |
Armodafinil | Armodafinil The metabolism of Paliperidone can be increased when combined with Armodafinil. |
Azacitidine Injection | Azacitidine Injection Azacitidine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Temsirolimus | Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Paliperidone. |
Lenalidomide | Lenalidomide Lenalidomide may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Nilotinib | Nilotinib The metabolism of Nilotinib can be decreased when combined with Paliperidone. |
Toremifene | Toremifene The risk or severity of QTc prolongation can be increased when Toremifene is combined with Paliperidone. |
Budesonide | Budesonide The metabolism of Paliperidone can be increased when combined with Budesonide. |
Chloramphenicol Injection | Chloramphenicol Injection The metabolism of Paliperidone can be decreased when combined with Chloramphenicol. |
Desmopressin | Desmopressin Desmopressin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
OnabotulinumtoxinA Injection | OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone. |
RimabotulinumtoxinB Injection | RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Paliperidone. |
Doripenem Injection | Doripenem Injection Paliperidone may decrease the excretion rate of Doripenem which could result in a higher serum level. |
Etravirine | Etravirine The serum concentration of Paliperidone can be decreased when it is combined with Etravirine. |
Arsenic Trioxide Injection | Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Paliperidone. |
Desvenlafaxine | Desvenlafaxine The risk or severity of adverse effects can be increased when Paliperidone is combined with Desvenlafaxine. |
Cevimeline | Cevimeline Cevimeline may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Nebivolol | Nebivolol Nebivolol may increase the orthostatic hypotensive activities of Paliperidone. |
Tretinoin | Tretinoin The metabolism of Paliperidone can be decreased when combined with Tretinoin. |
Bendamustine Injection | Bendamustine Injection The serum concentration of Bendamustine can be increased when it is combined with Paliperidone. |
Flecainide | Flecainide The metabolism of Flecainide can be decreased when combined with Paliperidone. |
Certolizumab Injection | Certolizumab Injection The metabolism of Paliperidone can be increased when combined with Certolizumab pegol. |
Irinotecan Injection | Irinotecan Injection The metabolism of Paliperidone can be decreased when combined with Irinotecan. |
Daptomycin Injection | Daptomycin Injection Daptomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Praziquantel | Praziquantel The metabolism of Paliperidone can be decreased when combined with Praziquantel. |
Methylnaltrexone Injection | Methylnaltrexone Injection Paliperidone may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. |
Rufinamide | Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Paliperidone. |
Silodosin | Silodosin The serum concentration of Silodosin can be increased when it is combined with Paliperidone. |
Midazolam | Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone. |
Naltrexone Injection | Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Paliperidone. |
Dexrazoxane Injection | Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Milnacipran | Milnacipran The risk or severity of adverse effects can be increased when Paliperidone is combined with Milnacipran. |
Plerixafor Injection | Plerixafor Injection Paliperidone may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
Fesoterodine | Fesoterodine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine. |
Degarelix Injection | Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Paliperidone. |
Betaxolol | Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Paliperidone. |
Iloperidone | Iloperidone Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone. |
Prasugrel | Prasugrel Paliperidone may decrease the excretion rate of Prasugrel which could result in a higher serum level. |
Lacosamide | Lacosamide The risk or severity of adverse effects can be increased when Paliperidone is combined with Lacosamide. |
Everolimus | Everolimus The serum concentration of Everolimus can be increased when it is combined with Paliperidone. |
Tolvaptan (low blood sodium) | Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Paliperidone. |
Dronedarone | Dronedarone Paliperidone may increase the QTc-prolonging activities of Dronedarone. |
AbobotulinumtoxinA Injection | AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone. |
Pralatrexate Injection | Pralatrexate Injection Paliperidone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
Palonosetron Injection | Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Paliperidone. |
Saxagliptin | Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Paliperidone. |
Telavancin Injection | Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Paliperidone. |
Romidepsin Injection | Romidepsin Injection The serum concentration of Romidepsin can be increased when it is combined with Paliperidone. |
Tapentadol | Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. |
Topotecan | Topotecan The serum concentration of Topotecan can be increased when it is combined with Paliperidone. |
Golimumab Injection | Golimumab Injection The metabolism of Paliperidone can be increased when combined with Golimumab. |
Pazopanib | Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Paliperidone. |
Asenapine | Asenapine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine. |
Vigabatrin | Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Paliperidone. |
Levonorgestrel | Levonorgestrel The metabolism of Paliperidone can be decreased when combined with Levonorgestrel. |
Oxymorphone | Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Paliperidone. |
Liraglutide Injection | Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Paliperidone. |
Tocilizumab Injection | Tocilizumab Injection The metabolism of Paliperidone can be increased when combined with Tocilizumab. |
Dalfampridine | Dalfampridine Paliperidone may decrease the excretion rate of Dalfampridine which could result in a higher serum level. |
Eribulin Injection | Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Paliperidone. |
IncobotulinumtoxinA Injection | IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Paliperidone. |
Cabazitaxel Injection | Cabazitaxel Injection The serum concentration of Cabazitaxel can be increased when it is combined with Paliperidone. |
Ceftaroline Injection | Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Lurasidone | Lurasidone Paliperidone may increase the hypotensive activities of Lurasidone. |
Acetaminophen Injection | Acetaminophen Injection Acetaminophen may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Vilazodone | Vilazodone The metabolism of Vilazodone can be decreased when combined with Paliperidone. |
Ipilimumab Injection | Ipilimumab Injection Paliperidone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. |
Denileukin Diftitox Injection | Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Terbutaline Injection | Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Paliperidone. |
Roflumilast | Roflumilast Paliperidone may decrease the excretion rate of Roflumilast which could result in a higher serum level. |
Linagliptin | Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Paliperidone. |
Rilpivirine | Rilpivirine The metabolism of Rilpivirine can be decreased when combined with Paliperidone. |
Telaprevir | Telaprevir The serum concentration of Glecaprevir can be increased when it is combined with Paliperidone. |
Cyclophosphamide Injection | Cyclophosphamide Injection The metabolism of Paliperidone can be decreased when combined with Cyclophosphamide. |
Abiraterone | Abiraterone The metabolism of Paliperidone can be decreased when combined with Abiraterone. |
Triptorelin Injection | Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Paliperidone. |
Rivaroxaban | Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Paliperidone. |
Ticagrelor | Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Paliperidone. |
Brentuximab Vedotin Injection | Brentuximab Vedotin Injection The serum concentration of Brentuximab vedotin can be increased when it is combined with Paliperidone. |
Ruxolitinib | Ruxolitinib Paliperidone may decrease the excretion rate of Ruxolitinib which could result in a higher serum level. |
Vandetanib | Vandetanib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Vandetanib. |
Clobazam | Clobazam The metabolism of Paliperidone can be decreased when combined with Clobazam. |
Vemurafenib | Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Paliperidone. |
Ivacaftor | Ivacaftor The serum concentration of Paliperidone can be increased when it is combined with Ivacaftor. |
Deferiprone | Deferiprone Paliperidone may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
Axitinib | Axitinib The serum concentration of Axitinib can be increased when it is combined with Paliperidone. |
Crizotinib | Crizotinib The serum concentration of Paliperidone can be increased when it is combined with Crizotinib. |
Cabergoline | Cabergoline The serum concentration of Paliperidone can be increased when it is combined with Cabergoline. |
Naloxone Injection | Naloxone Injection Naloxone may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Ambrisentan | Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Paliperidone. |
Fondaparinux Injection | Fondaparinux Injection Fondaparinux may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Ezogabine | Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Paliperidone. |
Carfilzomib Injection | Carfilzomib Injection The serum concentration of Carfilzomib can be increased when it is combined with Paliperidone. |
Enzalutamide | Enzalutamide The serum concentration of Paliperidone can be increased when it is combined with Enzalutamide. |
Mirabegron | Mirabegron The metabolism of Paliperidone can be decreased when combined with Mirabegron. |
Regorafenib | Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Paliperidone. |
Bosutinib | Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Paliperidone. |
Lorcaserin | Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Paliperidone. |
Teduglutide Injection | Teduglutide Injection Paliperidone may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
Bedaquiline | Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Paliperidone. |
Alogliptin | Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone. |
Ponatinib | Ponatinib The metabolism of Ponatinib can be decreased when combined with Paliperidone. |
Pomalidomide | Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Paliperidone. |
Ado-trastuzumab Emtansine Injection | Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Paliperidone. |
Apixaban | Apixaban The serum concentration of Apixaban can be increased when it is combined with Paliperidone. |
Canagliflozin | Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Paliperidone. |
Methazolamide | Methazolamide Methazolamide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Dabrafenib | Dabrafenib The serum concentration of Paliperidone can be increased when it is combined with Dabrafenib. |
Ospemifene | Ospemifene The metabolism of Paliperidone can be decreased when combined with Ospemifene. |
Trametinib | Trametinib Paliperidone may decrease the excretion rate of Trametinib which could result in a higher serum level. |
Dolutegravir | Dolutegravir The serum concentration of Dolutegravir can be increased when it is combined with Paliperidone. |
Afatinib | Afatinib The serum concentration of Afatinib can be increased when it is combined with Paliperidone. |
Levomilnacipran | Levomilnacipran The risk or severity of adverse effects can be increased when Paliperidone is combined with Levomilnacipran. |
Ertapenem Injection | Ertapenem Injection Ertapenem may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Vortioxetine | Vortioxetine The risk or severity of adverse effects can be increased when Paliperidone is combined with Vortioxetine. |
Perampanel | Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. |
Ibrutinib | Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Paliperidone. |
Lomitapide | Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Paliperidone. |
Avanafil | Avanafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Paliperidone. |
Ketorolac Injection | Ketorolac Injection Ketorolac may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Simeprevir | Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Paliperidone. |
Sofosbuvir | Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Paliperidone. |
Dapagliflozin | Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Paliperidone. |
Apremilast | Apremilast The metabolism of Paliperidone can be increased when combined with Apremilast. |
Droxidopa | Droxidopa The therapeutic efficacy of Droxidopa can be decreased when used in combination with Paliperidone. |
Ceritinib | Ceritinib The serum concentration of Paliperidone can be increased when it is combined with Ceritinib. |
Siltuximab Injection | Siltuximab Injection The metabolism of Paliperidone can be increased when combined with Siltuximab. |
Albiglutide Injection | Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Paliperidone. |
Eslicarbazepine | Eslicarbazepine The risk or severity of adverse effects can be increased when Paliperidone is combined with Eslicarbazepine. |
Belinostat Injection | Belinostat Injection The serum concentration of Belinostat can be increased when it is combined with Paliperidone. |
Idelalisib | Idelalisib The serum concentration of Idelalisib can be increased when it is combined with Paliperidone. |
Testosterone Injection | Testosterone Injection Testosterone may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Oritavancin Injection | Oritavancin Injection The metabolism of Paliperidone can be decreased when combined with Oritavancin. |
Empagliflozin | Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone. |
Vorapaxar | Vorapaxar The serum concentration of Paliperidone can be increased when it is combined with Vorapaxar. |
Hydrocodone | Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. |
Suvorexant | Suvorexant Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
Dulaglutide Injection | Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Paliperidone. |
Edoxaban | Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Paliperidone. |
Olaparib | Olaparib The metabolism of Olaparib can be decreased when combined with Paliperidone. |
Methamphetamine | Methamphetamine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Metamfetamine. |
Tasimelteon | Tasimelteon The risk or severity of adverse effects can be increased when Paliperidone is combined with Tasimelteon. |
Riociguat | Riociguat Paliperidone may decrease the antihypertensive activities of Riociguat. |
Nintedanib | Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Paliperidone. |
Secukinumab Injection | Secukinumab Injection The metabolism of Paliperidone can be increased when combined with Secukinumab. |
Risperidone Injection | Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone. |
Palbociclib | Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Paliperidone. |
Insulin Human Inhalation | Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Paliperidone. |
Lenvatinib | Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Paliperidone. |
Naloxegol | Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Paliperidone. |
Panobinostat | Panobinostat The metabolism of Paliperidone can be decreased when combined with Panobinostat. |
Haloperidol Injection | Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Paliperidone. |
Ivabradine | Ivabradine The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ivabradine. |
Amiloride | Amiloride Amiloride may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Isavuconazonium Injection | Isavuconazonium Injection The serum concentration of Paliperidone can be increased when it is combined with Isavuconazonium. |
Macitentan | Macitentan Paliperidone may decrease the excretion rate of Macitentan which could result in a higher serum level. |
Flibanserin | Flibanserin The serum concentration of Paliperidone can be increased when it is combined with Flibanserin. |
Rolapitant | Rolapitant The metabolism of Paliperidone can be decreased when combined with Rolapitant. |
Daclatasvir | Daclatasvir The serum concentration of Paliperidone can be increased when it is combined with Daclatasvir. |
Brexpiprazole | Brexpiprazole Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole. |
Ziprasidone Injection | Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Paliperidone. |
Cariprazine | Cariprazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Cariprazine. |
Penicillin G Procaine Injection | Penicillin G Procaine Injection Paliperidone may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
Eluxadoline | Eluxadoline The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Eluxadoline. |
Insulin Degludec (rDNA Origin) Injection | Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Paliperidone. |
Cobimetinib | Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Paliperidone. |
Trabectedin Injection | Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Paliperidone. |
Osimertinib | Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Paliperidone. |
Ixazomib | Ixazomib Paliperidone may decrease the excretion rate of Ixazomib which could result in a higher serum level. |
Lesinurad | Lesinurad Paliperidone may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
Amphotericin B Liposomal Injection | Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Dexamethasone Injection | Dexamethasone Injection The metabolism of Paliperidone can be increased when combined with Dexamethasone. |
Brivaracetam Injection | Brivaracetam Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Brivaracetam. |
Venetoclax | Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Paliperidone. |
Cobicistat | Cobicistat The metabolism of Paliperidone can be decreased when combined with Cobicistat. |
Midodrine | Midodrine The therapeutic efficacy of Midodrine can be decreased when used in combination with Paliperidone. |
Selexipag | Selexipag The serum concentration of Selexipag can be increased when it is combined with Paliperidone. |
Pimavanserin | Pimavanserin The risk or severity of adverse effects can be increased when Paliperidone is combined with Pimavanserin. |
Diphenhydramine Injection | Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Paliperidone. |
Furosemide Injection | Furosemide Injection Furosemide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Rucaparib | Rucaparib The metabolism of Rucaparib can be decreased when combined with Paliperidone. |
Lixisenatide Injection | Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Paliperidone. |
Ribociclib | Ribociclib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ribociclib. |
Doxepin (Insomnia) | Doxepin (Insomnia) Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin. |
Deutetrabenazine | Deutetrabenazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Deutetrabenazine. |
Valbenazine | Valbenazine Paliperidone may decrease the excretion rate of Valbenazine which could result in a higher serum level. |
Deflazacort | Deflazacort The metabolism of Paliperidone can be increased when combined with Deflazacort. |
Safinamide | Safinamide The therapeutic efficacy of Safinamide can be decreased when used in combination with Paliperidone. |
Naldemedine | Naldemedine Paliperidone may decrease the excretion rate of Naldemedine which could result in a higher serum level. |
Midostaurin | Midostaurin The metabolism of Paliperidone can be decreased when combined with Midostaurin. |
Neratinib | Neratinib The serum concentration of Paliperidone can be increased when it is combined with Neratinib. |
Enasidenib | Enasidenib The metabolism of Paliperidone can be decreased when combined with Enasidenib. |
Inotuzumab Ozogamicin Injection | Inotuzumab Ozogamicin Injection The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Paliperidone. |
Benznidazole | Benznidazole Paliperidone may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
Copanlisib Injection | Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Paliperidone. |
Delafloxacin | Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Paliperidone. |
Abemaciclib | Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Paliperidone. |
Betrixaban | Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Paliperidone. |
Acalabrutinib | Acalabrutinib The metabolism of Paliperidone can be decreased when combined with Acalabrutinib. |
Letermovir | Letermovir The metabolism of Paliperidone can be decreased when combined with Letermovir. |
Semaglutide Injection | Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Paliperidone. |
Tetrabenazine | Tetrabenazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrabenazine. |
Ertugliflozin | Ertugliflozin The serum concentration of Ertugliflozin can be increased when it is combined with Paliperidone. |
Buprenorphine Injection | Buprenorphine Injection Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
Apalutamide | Apalutamide The serum concentration of Paliperidone can be decreased when it is combined with Apalutamide. |
Fostamatinib | Fostamatinib The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Paliperidone. |
Avatrombopag | Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Paliperidone. |
Baricitinib | Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Paliperidone. |
Lofexidine | Lofexidine The therapeutic efficacy of Paliperidone can be increased when used in combination with Lofexidine. |
Plazomicin Injection | Plazomicin Injection Paliperidone may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
Eliglustat | Eliglustat The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Eliglustat. |
Encorafenib | Encorafenib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Encorafenib. |
Binimetinib | Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Paliperidone. |
Ivosidenib | Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Paliperidone. |
Lusutrombopag | Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Paliperidone. |
Elagolix | Elagolix The serum concentration of Elagolix can be increased when it is combined with Paliperidone. |
Doravirine | Doravirine The metabolism of Doravirine can be decreased when combined with Paliperidone. |
Tafenoquine | Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Paliperidone. |
Cannabidiol | Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Paliperidone. |
Dacomitinib | Dacomitinib The serum concentration of Paliperidone can be increased when it is combined with Dacomitinib. |
Duvelisib | Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Paliperidone. |
Omadacycline | Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Paliperidone. |
Sarecycline | Sarecycline The serum concentration of Paliperidone can be increased when it is combined with Sarecycline. |
Stiripentol | Stiripentol The metabolism of Paliperidone can be decreased when combined with Stiripentol. |
Talazoparib | Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Paliperidone. |
Gilteritinib | Gilteritinib The therapeutic efficacy of Paliperidone can be decreased when used in combination with Gilteritinib. |
Glasdegib | Glasdegib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Glasdegib. |
Lorlatinib | Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Paliperidone. |
Larotrectinib | Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Paliperidone. |
Paclitaxel (with albumin) Injection | Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Paliperidone. |
Rifamycin | Rifamycin The serum concentration of Rifamycin can be increased when it is combined with Paliperidone. |
Prucalopride | Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Paliperidone. |
Emapalumab-lzsg Injection | Emapalumab-lzsg Injection The metabolism of Paliperidone can be increased when combined with Emapalumab. |
Siponimod | Siponimod The risk or severity of hypertension can be increased when Paliperidone is combined with Siponimod. |
Acyclovir Ophthalmic | Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Erdafitinib | Erdafitinib The serum concentration of Paliperidone can be increased when it is combined with Erdafitinib. |
Brexanolone Injection | Brexanolone Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Brexanolone. |
Solriamfetol | Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Paliperidone. |
Darolutamide | Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Paliperidone. |
Triclabendazole | Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Paliperidone. |
Entrectinib | Entrectinib The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Entrectinib. |
Istradefylline | Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Paliperidone. |
Pitolisant | Pitolisant The serum concentration of Paliperidone can be decreased when it is combined with Pitolisant. |
Fedratinib | Fedratinib The serum concentration of Fedratinib can be increased when it is combined with Paliperidone. |
Lefamulin | Lefamulin Paliperidone may increase the QTc-prolonging activities of Lefamulin. |
Phenytoin Injection | Phenytoin Injection The risk or severity of adverse effects can be increased when Phenytoin is combined with Paliperidone. |
Fosphenytoin Injection | Fosphenytoin Injection The risk or severity of adverse effects can be increased when Paliperidone is combined with Fosphenytoin. |
Enfortumab vedotin-ejfv Injection | Enfortumab vedotin-ejfv Injection The serum concentration of Enfortumab vedotin can be increased when it is combined with Paliperidone. |
Lumateperone | Lumateperone The risk or severity of adverse effects can be increased when Paliperidone is combined with Lumateperone. |
Lasmiditan | Lasmiditan The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Lasmiditan. |
Ubrogepant | Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Paliperidone. |
Tazemetostat | Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Paliperidone. |
Cenobamate | Cenobamate The serum concentration of Paliperidone can be decreased when it is combined with Cenobamate. |
Selumetinib | Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Paliperidone. |
Rimegepant | Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Paliperidone. |
Tucatinib | Tucatinib Paliperidone may decrease the excretion rate of Tucatinib which could result in a higher serum level. |
Remdesivir Injection | Remdesivir Injection The serum concentration of Remdesivir can be increased when it is combined with Paliperidone. |
Ripretinib | Ripretinib The serum concentration of Ripretinib can be increased when it is combined with Paliperidone. |
Selpercatinib | Selpercatinib The risk or severity of hypertension can be increased when Paliperidone is combined with Selpercatinib. |
Lemborexant | Lemborexant The risk or severity of adverse effects can be increased when Paliperidone is combined with Lemborexant. |
Fenfluramine | Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Paliperidone. |
Fostemsavir | Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Paliperidone. |
Octreotide | Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Paliperidone. |
Belantamab Mafodotin-blmf Injection | Belantamab Mafodotin-blmf Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Paliperidone. |
Pralsetinib | Pralsetinib The serum concentration of Pralsetinib can be increased when it is combined with Paliperidone. |
Opicapone | Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Paliperidone. |
Satralizumab-mwge Injection | Satralizumab-mwge Injection The serum concentration of Paliperidone can be decreased when it is combined with Satralizumab. |
Naxitamab-gqgk Injection | Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Paliperidone is combined with Naxitamab. |
Relugolix | Relugolix The serum concentration of Relugolix can be increased when it is combined with Paliperidone. |
Progestin-Only (drospirenone) Oral Contraceptives | Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Viloxazine | Viloxazine The risk or severity of adverse effects can be increased when Paliperidone is combined with Viloxazine. |
Tobramycin Injection | Tobramycin Injection Tobramycin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Theophylline | Theophylline The metabolism of Paliperidone can be decreased when combined with Theophylline. |
Fenoprofen | Fenoprofen Fenoprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Indomethacin | Indomethacin Indomethacin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Mefenamic Acid | Mefenamic Acid Mefenamic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Naproxen | Naproxen Naproxen may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Tolmetin | Tolmetin Tolmetin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Sulindac | Sulindac Sulindac may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Trazodone | Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Paliperidone. |
Isotretinoin | Isotretinoin Isotretinoin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Sucralfate | Sucralfate Sucralfate may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Hydroxyurea | Hydroxyurea The metabolism of Paliperidone can be decreased when combined with Hydroxyurea. |
Floxuridine | Floxuridine Floxuridine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Phenobarbital | Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Paliperidone. |
Metaxalone | Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Paliperidone. |
Methotrexate Injection | Methotrexate Injection Methotrexate may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Levorphanol | Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Paliperidone. |
Primidone | Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Paliperidone. |
Methsuximide | Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Paliperidone. |
Diethylpropion | Diethylpropion The therapeutic efficacy of Paliperidone can be decreased when used in combination with Diethylpropion. |
Chlorpromazine | Chlorpromazine Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Diazepam | Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Paliperidone. |
Oxazepam | Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Paliperidone. |
Flurazepam | Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone. |
Clorazepate | Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Paliperidone. |
Lorazepam | Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Paliperidone. |
Phenoxybenzamine | Phenoxybenzamine Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Carmustine | Carmustine Carmustine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Amantadine | Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Paliperidone. |
Codeine | Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Paliperidone. |
Meprobamate | Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone. |
Chlordiazepoxide | Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paliperidone. |
Bromocriptine | Bromocriptine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine. |
Metaproterenol | Metaproterenol The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Paliperidone. |
Tranylcypromine | Tranylcypromine The metabolism of Paliperidone can be decreased when combined with Tranylcypromine. |
Phenelzine | Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Paliperidone. |
Procarbazine | Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Paliperidone. |
Ergoloid Mesylates | Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone. |
Tetracycline | Tetracycline Tetracycline may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Minocycline | Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. |
Prochlorperazine | Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Paliperidone. |
Thioridazine | Thioridazine Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Trifluoperazine | Trifluoperazine Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Bleomycin | Bleomycin Bleomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Dapsone | Dapsone The metabolism of Paliperidone can be decreased when combined with Dapsone. |
Sulfadiazine | Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Paliperidone. |
Oxycodone | Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone. |
Methadone | Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Paliperidone. |
Oxybutynin | Oxybutynin The metabolism of Paliperidone can be decreased when combined with Oxybutynin. |
Benztropine | Benztropine The risk or severity of adverse effects can be increased when Paliperidone is combined with Benzatropine. |
Maprotiline | Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Paliperidone. |
Ibuprofen | Ibuprofen Ibuprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Trihexyphenidyl | Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Paliperidone. |
Orphenadrine | Orphenadrine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
Perphenazine | Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone. |
Azathioprine | Azathioprine Azathioprine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Fluphenazine | Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone. |
Phentermine | Phentermine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Phentermine. |
Methylphenidate | Methylphenidate The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate. |
Amoxapine | Amoxapine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine. |
Sulfasalazine | Sulfasalazine Sulfasalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Hydrocortisone | Hydrocortisone The metabolism of Paliperidone can be decreased when combined with Hydrocortisone. |
Doxorubicin | Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Paliperidone. |
Dactinomycin | Dactinomycin The serum concentration of Paliperidone can be increased when it is combined with Dactinomycin. |
Phenazopyridine | Phenazopyridine Phenazopyridine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Carbamazepine | Carbamazepine The metabolism of Paliperidone can be decreased when combined with Carbamazepine. |
Molindone | Molindone The risk or severity of adverse effects can be increased when Paliperidone is combined with Molindone. |
Methyldopa | Methyldopa The therapeutic efficacy of Paliperidone can be decreased when used in combination with Methyldopa. |
Clonidine | Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Paliperidone. |
Prazosin | Prazosin Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Hydralazine | Hydralazine Paliperidone may decrease the excretion rate of Hydralazine which could result in a higher serum level. |
Cimetidine | Cimetidine The metabolism of Paliperidone can be decreased when combined with Cimetidine. |
Gentamicin Injection | Gentamicin Injection Gentamicin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Warfarin | Warfarin Paliperidone may decrease the excretion rate of Warfarin which could result in a higher serum level. |
Clonazepam | Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Paliperidone. |
Loperamide | Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Paliperidone. |
Promethazine | Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Paliperidone. |
Meclofenamate | Meclofenamate Meclofenamic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Daunorubicin | Daunorubicin The metabolism of Paliperidone can be increased when combined with Daunorubicin. |
Nitrofurantoin | Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Digoxin | Digoxin Paliperidone may decrease the excretion rate of Digoxin which could result in a higher serum level. |
Loxapine | Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone. |
Chloroquine | Chloroquine The metabolism of Paliperidone can be decreased when combined with Chloroquine. |
Quinine | Quinine The metabolism of Paliperidone can be decreased when combined with Quinine. |
Ethosuximide | Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Paliperidone. |
Triamterene | Triamterene Triamterene may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Chlorothiazide | Chlorothiazide Chlorothiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Chlorthalidone | Chlorthalidone Chlorthalidone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Metolazone | Metolazone Metolazone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Isosorbide | Isosorbide Isosorbide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Clindamycin Injection | Clindamycin Injection The metabolism of Paliperidone can be decreased when combined with Clindamycin. |
Secobarbital | Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone. |
Desipramine | Desipramine The metabolism of Paliperidone can be decreased when combined with Desipramine. |
Amitriptyline | Amitriptyline Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amitriptyline. |
Imipramine | Imipramine Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Probenecid | Probenecid Probenecid may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Quinidine | Quinidine Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quinidine. |
Procainamide | Procainamide The metabolism of Procainamide can be decreased when combined with Paliperidone. |
Isoniazid | Isoniazid The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Paliperidone. |
Pyrazinamide | Pyrazinamide Pyrazinamide may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Rifampin | Rifampin The serum concentration of Paliperidone can be decreased when it is combined with Rifampicin. |
Disopyramide | Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Paliperidone. |
Valproic Acid | Valproic Acid The serum concentration of Paliperidone can be increased when it is combined with Valproic acid. |
Tamoxifen | Tamoxifen The metabolism of Paliperidone can be decreased when combined with Tamoxifen. |
Butabarbital | Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone. |
Levothyroxine | Levothyroxine The serum concentration of Paliperidone can be decreased when it is combined with Levothyroxine. |
Liothyronine | Liothyronine Liothyronine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Methimazole | Methimazole The metabolism of Paliperidone can be decreased when combined with Methimazole. |
Chlorpropamide | Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Paliperidone. |
Tolbutamide | Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone. |
Tolazamide | Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Paliperidone. |
Dextromethorphan | Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Paliperidone. |
Cyclobenzaprine | Cyclobenzaprine The risk or severity of CNS depression can be increased when Paliperidone is combined with Cyclobenzaprine. |
Niacin | Niacin The metabolism of Paliperidone can be decreased when combined with Niacin. |
Baclofen | Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Paliperidone. |
Doxylamine | Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone. |
Cyproheptadine | Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Paliperidone. |
Clemastine | Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Paliperidone. |
Chlorpheniramine | Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Paliperidone. |
Brompheniramine | Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Paliperidone. |
Meclizine | Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Paliperidone. |
Ethambutol | Ethambutol Ethambutol may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Methyclothiazide | Methyclothiazide Methyclothiazide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Hydrochlorothiazide | Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Paliperidone. |
Dantrolene | Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Paliperidone. |
Chlorzoxazone | Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Paliperidone. |
Carisoprodol | Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Paliperidone. |
Methocarbamol | Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Paliperidone. |
Pyridoxine | Pyridoxine Pyridoxine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Folic Acid | Folic Acid Folic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Disulfiram | Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Paliperidone. |
Propranolol (Cardiovascular) | Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Propranolol is combined with Paliperidone. |
Minoxidil | Minoxidil Paliperidone may decrease the antihypertensive activities of Minoxidil. |
Pseudoephedrine | Pseudoephedrine The therapeutic efficacy of Paliperidone can be decreased when used in combination with Pseudoephedrine. |
Nortriptyline | Nortriptyline Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline. |
Spironolactone | Spironolactone Spironolactone may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Amphotericin B Injection | Amphotericin B Injection Amphotericin B may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Phytonadione | Phytonadione Phylloquinone may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Amikacin Injection | Amikacin Injection Amikacin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Nadolol | Nadolol Nadolol may increase the orthostatic hypotensive activities of Paliperidone. |
Butorphanol Injection | Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone. |
Nalbuphine Injection | Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Paliperidone. |
Allopurinol | Allopurinol Allopurinol may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Oxytocin Injection | Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Paliperidone. |
Trimethobenzamide | Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Paliperidone. |
Clomiphene | Clomiphene The serum concentration of Clomifene can be increased when it is combined with Paliperidone. |
Flavoxate | Flavoxate Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Flavoxate. |
Papaverine | Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Paliperidone. |
Fluorouracil Injection | Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Paliperidone. |
Colchicine | Colchicine The serum concentration of Colchicine can be increased when it is combined with Paliperidone. |
Cefaclor | Cefaclor Cefaclor may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cefadroxil | Cefadroxil Cefadroxil may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cefazolin Injection | Cefazolin Injection Cefazolin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cephalexin | Cephalexin Cephalexin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cefoxitin Injection | Cefoxitin Injection Cefoxitin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Dacarbazine | Dacarbazine Dacarbazine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Acetazolamide | Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Paliperidone. |
Cefotaxime Injection | Cefotaxime Injection Cefotaxime may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Calcitonin Salmon Injection | Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Ketoconazole | Ketoconazole The metabolism of Paliperidone can be decreased when combined with Ketoconazole. |
Pyrantel | Pyrantel The risk or severity of adverse effects can be increased when Paliperidone is combined with Pyrantel. |
Vincristine Injection | Vincristine Injection The excretion of Vincristine can be decreased when combined with Paliperidone. |
Captopril | Captopril Paliperidone may decrease the antihypertensive activities of Captopril. |
Dipyridamole | Dipyridamole The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Paliperidone. |
Isoxsuprine | Isoxsuprine The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Paliperidone. |
Vinblastine | Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Paliperidone. |
Ethacrynic Acid | Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Colistimethate Injection | Colistimethate Injection Colistimethate may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Metoprolol | Metoprolol The metabolism of Metoprolol can be decreased when combined with Paliperidone. |
Hydroxyzine | Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Paliperidone. |
Thiothixene | Thiothixene The risk or severity of adverse effects can be increased when Paliperidone is combined with Thiothixene. |
Aspirin | Aspirin Acetylsalicylic acid may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Salsalate | Salsalate Salsalate may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Alprazolam | Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Paliperidone. |
Temazepam | Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone. |
Triazolam | Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Paliperidone. |
Dicyclomine | Dicyclomine Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine. |
Hyoscyamine | Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Paliperidone. |
Propantheline | Propantheline Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Propantheline. |
Trimethoprim | Trimethoprim Trimethoprim may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Diltiazem | Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Paliperidone. |
Nifedipine | Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Paliperidone. |
Timolol | Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Paliperidone. |
Verapamil | Verapamil Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Atenolol | Atenolol Atenolol may increase the orthostatic hypotensive activities of Paliperidone. |
Pindolol | Pindolol Pindolol may increase the orthostatic hypotensive activities of Paliperidone. |
Cisplatin Injection | Cisplatin Injection Paliperidone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
Diflunisal | Diflunisal Diflunisal may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Piroxicam | Piroxicam Piroxicam may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Bumetanide | Bumetanide Bumetanide may increase the excretion rate of Paliperidone which could result in a lower serum level and potentially a reduction in efficacy. |
Etoposide | Etoposide The serum concentration of Paliperidone can be increased when it is combined with Etoposide. |
Glyburide | Glyburide The therapeutic efficacy of Paliperidone can be decreased when used in combination with Glyburide. |
Glipizide | Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Paliperidone. |
Indapamide | Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Paliperidone. |
Amoxicillin | Amoxicillin Amoxicillin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Oxacillin Injection | Oxacillin Injection Oxacillin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Pentoxifylline | Pentoxifylline The risk or severity of hypotension, dyspepsia, and headache can be increased when Pentoxifylline is combined with Paliperidone. |
Pentamidine Injection | Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Paliperidone. |
Ceftriaxone Injection | Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Labetalol | Labetalol Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Auranofin | Auranofin Auranofin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Leuprolide Injection | Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Paliperidone. |
Gemfibrozil | Gemfibrozil Gemfibrozil may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Guanabenz | Guanabenz The therapeutic efficacy of Guanabenz can be decreased when used in combination with Paliperidone. |
Dipivefrin Ophthalmic | Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Ceftazidime Injection | Ceftazidime Injection Ceftazidime may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Ketoprofen | Ketoprofen Ketoprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cefotetan Injection | Cefotetan Injection Cefotetan may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Pimozide | Pimozide The metabolism of Paliperidone can be decreased when combined with Pimozide. |
Enalapril | Enalapril Paliperidone may decrease the antihypertensive activities of Enalapril. |
Flurbiprofen | Flurbiprofen Flurbiprofen may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Amiodarone | Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Paliperidone. |
Aztreonam Injection | Aztreonam Injection Aztreonam may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Buspirone | Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Paliperidone. |
Lovastatin | Lovastatin The metabolism of Paliperidone can be decreased when combined with Lovastatin. |
Ciprofloxacin | Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Paliperidone. |
Mesalamine | Mesalamine Mesalazine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Diclofenac | Diclofenac Diclofenac may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Fluoxetine | Fluoxetine The serum concentration of Paliperidone can be increased when it is combined with Fluoxetine. |
Nimodipine | Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Paliperidone. |
Clozapine | Clozapine Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Estazolam | Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Paliperidone. |
Idarubicin | Idarubicin The metabolism of Paliperidone can be decreased when combined with Idarubicin. |
Ofloxacin | Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Paliperidone. |
Didanosine | Didanosine Didanosine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Pentostatin Injection | Pentostatin Injection Pentostatin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Clarithromycin | Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Paliperidone. |
Benazepril | Benazepril Paliperidone may decrease the antihypertensive activities of Benazepril. |
Etodolac | Etodolac Etodolac may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Felodipine | Felodipine The metabolism of Felodipine can be decreased when combined with Paliperidone. |
Fosinopril | Fosinopril Fosinopril may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Nabumetone | Nabumetone Nabumetone may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Pravastatin | Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Paliperidone. |
Quinapril | Quinapril Paliperidone may decrease the antihypertensive activities of Quinapril. |
Ramipril | Ramipril Paliperidone may decrease the antihypertensive activities of Ramipril. |
Simvastatin | Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Paliperidone. |
Amlodipine | Amlodipine The risk or severity of hypotension can be increased when Paliperidone is combined with Amlodipine. |
Teniposide Injection | Teniposide Injection The metabolism of Paliperidone can be decreased when combined with Teniposide. |
Itraconazole | Itraconazole The metabolism of Paliperidone can be decreased when combined with Itraconazole. |
Lisinopril | Lisinopril Lisinopril may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Oxaprozin | Oxaprozin Oxaprozin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Sotalol | Sotalol The metabolism of Sotalol can be decreased when combined with Paliperidone. |
Bisoprolol | Bisoprolol The serum concentration of Paliperidone can be increased when it is combined with Bisoprolol. |
Zolpidem | Zolpidem Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
Doxazosin | Doxazosin Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Terazosin | Terazosin Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Isradipine | Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Paliperidone. |
Omeprazole | Omeprazole The metabolism of Paliperidone can be decreased when combined with Omeprazole. |
Cisapride | Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Paliperidone. |
Gabapentin | Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Paliperidone. |
Fluvastatin | Fluvastatin The metabolism of Paliperidone can be decreased when combined with Fluvastatin. |
Venlafaxine | Venlafaxine The metabolism of Paliperidone can be decreased when combined with Venlafaxine. |
Stavudine | Stavudine Stavudine may increase the neurotoxic activities of Paliperidone. |
Fluvoxamine | Fluvoxamine The metabolism of Paliperidone can be decreased when combined with Fluvoxamine. |
Nefazodone | Nefazodone Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone. |
Lamotrigine | Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Paliperidone. |
Losartan | Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Paliperidone. |
Valacyclovir | Valacyclovir Valaciclovir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Tramadol | Tramadol The risk or severity of serotonin syndrome can be increased when Paliperidone is combined with Tramadol. |
Vinorelbine Injection | Vinorelbine Injection The metabolism of Paliperidone can be decreased when combined with Vinorelbine. |
Carboplatin Injection | Carboplatin Injection Carboplatin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Moexipril | Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Paliperidone. |
Lansoprazole | Lansoprazole The metabolism of Paliperidone can be decreased when combined with Lansoprazole. |
Ifosfamide Injection | Ifosfamide Injection The metabolism of Paliperidone can be decreased when combined with Ifosfamide. |
Nicardipine | Nicardipine Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Bupropion | Bupropion The metabolism of Paliperidone can be decreased when combined with Bupropion. |
Ticlopidine | Ticlopidine The metabolism of Paliperidone can be decreased when combined with Ticlopidine. |
Saquinavir | Saquinavir The metabolism of Paliperidone can be decreased when combined with Saquinavir. |
Metformin | Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone. |
Nisoldipine | Nisoldipine The risk or severity of hypotension can be increased when Nisoldipine is combined with Paliperidone. |
Lamivudine | Lamivudine Lamivudine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Riluzole | Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Paliperidone. |
Acarbose | Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Paliperidone. |
Glimepiride | Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Paliperidone. |
Gemcitabine Injection | Gemcitabine Injection The serum concentration of Paliperidone can be increased when it is combined with Gemcitabine. |
Indinavir | Indinavir The metabolism of Paliperidone can be decreased when combined with Indinavir. |
Ritonavir | Ritonavir The serum concentration of Paliperidone can be increased when it is combined with Ritonavir. |
Docetaxel Injection | Docetaxel Injection The metabolism of Paliperidone can be decreased when combined with Docetaxel. |
Cidofovir Injection | Cidofovir Injection Cidofovir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Meropenem Injection | Meropenem Injection Meropenem may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Clomipramine | Clomipramine The metabolism of Paliperidone can be decreased when combined with Clomipramine. |
Fosfomycin | Fosfomycin Fosfomycin may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Mirtazapine | Mirtazapine Paliperidone may increase the serotonergic activities of Mirtazapine. |
Trandolapril | Trandolapril Paliperidone may decrease the antihypertensive activities of Trandolapril. |
Topiramate | Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Paliperidone. |
Valsartan | Valsartan Paliperidone may decrease the antihypertensive activities of Valsartan. |
Insulin Lispro Injection | Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Paliperidone. |
Pramipexole | Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Paliperidone. |
Donepezil | Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Paliperidone. |
Nelfinavir | Nelfinavir The metabolism of Paliperidone can be decreased when combined with Nelfinavir. |
Fexofenadine | Fexofenadine The serum concentration of Paliperidone can be increased when it is combined with Fexofenadine. |
Azithromycin | Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Paliperidone. |
Carvedilol | Carvedilol Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Nilutamide | Nilutamide Nilutamide may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Flutamide | Flutamide Flutamide may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Selegiline | Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Paliperidone. |
Bicalutamide | Bicalutamide The metabolism of Paliperidone can be decreased when combined with Bicalutamide. |
Sertraline | Sertraline The risk or severity of adverse effects can be increased when Sertraline is combined with Paliperidone. |
Propafenone | Propafenone The metabolism of Paliperidone can be decreased when combined with Propafenone. |
Irbesartan | Irbesartan Paliperidone may decrease the antihypertensive activities of Irbesartan. |
Tamsulosin | Tamsulosin Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Ropinirole | Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Paliperidone. |
Finasteride | Finasteride The metabolism of Paliperidone can be decreased when combined with Finasteride. |
Quetiapine | Quetiapine Quetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone. |
Cefepime Injection | Cefepime Injection Cefepime may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cefprozil | Cefprozil Cefprozil may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cefpodoxime | Cefpodoxime Cefpodoxime may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Cetirizine | Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Paliperidone. |
Paroxetine | Paroxetine The metabolism of Paliperidone can be decreased when combined with Paroxetine. |
Tolcapone | Tolcapone The therapeutic efficacy of Tolcapone can be decreased when used in combination with Paliperidone. |
Citalopram | Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Paliperidone. |
Capecitabine | Capecitabine Capecitabine may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Efavirenz | Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Paliperidone. |
Abacavir | Abacavir Abacavir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Sildenafil | Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Paliperidone. |
Pioglitazone | Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Paliperidone. |
Celecoxib | Celecoxib The metabolism of Paliperidone can be decreased when combined with Celecoxib. |
Rosiglitazone | Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Paliperidone. |
Tolterodine | Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Paliperidone. |
Thalidomide | Thalidomide Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
Oseltamivir | Oseltamivir Oseltamivir may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Balsalazide | Balsalazide Balsalazide may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Nateglinide | Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Paliperidone. |
Galantamine | Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Paliperidone. |
Levetiracetam | Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Paliperidone. |
Rabeprazole | Rabeprazole Rabeprazole may decrease the excretion rate of Paliperidone which could result in a higher serum level. |
Terbinafine | Terbinafine The metabolism of Paliperidone can be decreased when combined with Terbinafine. |
Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists